Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · KYNTRA BIO, INC. (KYNB)

Kyntra Bio adds Andrew Singer to board; Maykin Ho steps down; CEO agreement renewed

Neutral Impact 3 of 5 leadership Written later

Kyntra Bio appointed Andrew E. Singer, MBA, as a Class III director effective October 1, 2026, and named him to the Audit Committee. Director Maykin Ho, Ph.D., resigned from the board effective September 30, 2026, and the filing says her resignation was not the result of any disagreement with the company. The company also entered a new three-year change in control and severance agreement with CEO Thane Wettig, which the filing says has no material changes to compensation or benefits.

Key points

  • Andrew E. Singer, MBA, appointed Class III director effective October 1, 2026, with a term expiring in 2029 and a seat on the Audit Committee
  • Maykin Ho, Ph.D., resigned from the board effective September 30, 2026; she joined the board in December 2018
  • New change in control and severance agreement with CEO Thane Wettig dated September 30, 2026, with a term ending October 2, 2029, replacing the prior agreement
  • Filing states there were no material changes to compensation or benefits under the CEO agreement

The filing

CompanyKYNTRA BIO, INC. (KYNB)
Form8-K, current report
Filed with the SECOct 1, 2026, 7:30 AM ET
Accession number0001193125-26-409819

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:28 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 01, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.